Abstract: This invention provides methods for utilizing a PTPase inhibiting compounds and one or more insulins in methods for use in control and maintenance of type II diabetes in a mammal, for improving the cardiovascular and cerebrovascular risk profiles, reduction of hyperlipidemia, lowering low density lipoprotein blood levels, lowering free fatty acid blood levels and triglyceride levels and inhibition, prevention or reduction of atherosclerosis in a type II diabetic, or the risk factors thereof.

Abstract: This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.

Abstract: This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.

Abstract: This invention provides methods of using Protein-tyrosine phosphatase (PTPase) inhibitors for lowering the cardiovascular risk profile in mammals experiencing or subject to type II diabetes or Syndrome X, including lowering levels of blood lipoproteins, free fatty acids and triglycerides, as well as treating, preventing or inhibiting atherosclerosis and other cardiovascular and cerebebrovascular disorders.

Abstract: This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.

Abstract: This invention relates to pharmaceutical compositions and methods of treatment utilizing a PTPase (protein-tyrosine phosphatase) inhibitors and a glucosidase inhibitor, such as miglitol or acarbose, to lower the risk of cardiovascular disease and cardiovascular events in a mammal experiencing or subject to type II diabetes in mammals experiencing or subject to Syndrome X or type II diabetes (non-insulin-dependent diabetes mellitus), preferably in human type II diabetics.

Abstract: This invention provides pharmaceutical compositions and methods of treatment and control of Syndrome X or type II diabetes in a mammal utilizing a combination of a sulfonylurea agent and a protein-tyrosine phosphatase (PTPase) inhibitors.

Abstract: This invention relates to pharmaceutical compositions and methods of treatment utilizing a PTPase (protein-tyrosine phosphatase) inhibitors and an antilipemic agent, such as a bile acid sequestrants, a fibric acid derivative, an HMG-CoA reductase inhibitors, lipase inhibitor or a nicotinic acid derivative, to lower the risk of cardiovascular disease and cardiovascular events in a mammal experiencing or subject to type II diabetes in mammals experiencing or subject to type II diabetes (non-insulin-dependent diabetes mellitus), preferably in human type II diabetics, or in a mammal experiencing or subject to Syndrome X.

Abstract: This invention provides methods for utilizing a PTPase inhibiting compounds and one or more insulins in methods for use in control and maintenance of type II diabetes in a mammal, for improving the cardiovascular and cerebrovascular risk profiles, reduction of hyperlipidemia, lowering low density lipoprotein blood levels, lowering free fatty acid blood levels and triglyceride levels and inhibition, prevention or reduction of atherosclerosis in a type II diabetic, or the risk factors thereof.

Abstract: The invention relates to cementitious building board, such as gypsum board, having reinforcing strips along one or more of its edges. Such strips can be incorporated in such board faced with paper or other sheet material by cutting back the core leaving the edges of the sheets projecting, applying the strip and returning the edges of the sheets, to be adhesively secured to the face of the strip. The edge may have any desired profile but of particular interest is a board or tile having a groove, or kerf along at least two opposite edges of the core, the reinforcing strips being corresponding channel sections with lateral flanges to which the edges of the facing sheets are secured. The reinforced boards are useful in the production of ceilings and walls and, in the case of panels and tiles with kerfed edges, can be mounted by invisible or "secret" fixing devices.

Abstract: The invention relates to the manufacture of cementitious board, such as gypsum board, faced with paper or other sheets and having an improved accuracy of edge profile. A sheet to be folded at the lateral edges of the board is scored, and quick-setting adhesive, preferably a hot melt adhesive, is applied along the lines of folding. The sheet is then folded to the desired configuration and held until the adhesive has set thus establishing an accurate profile that withstands the action of the aqueous slurry of cementitious material and the application of the other sheet. The invention can be applied to various profiles, including square edge, tapered edge, rebated and tongue-and-groove.